Biogen inc stock.

The following ETFs maintain exposure to Biogen Inc. ( BIIB ). ETF holdings data are updated once a day, and are subject to change. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol.Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation. CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (“3M”), to the Company’s Board of Directors (the “Board ...Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing.Latest news about Biogen Inc. RBC Adjusts Biogen's Price Target to $379 From $341, Keeps Outperform Rating. Jul. 26. MT. RBC Adjusts Price Target on Biogen to $379 …

Find the latest Eisai Co., Ltd. (4523.T) stock quote, history, news and other vital information to help you with your stock trading and investing.The low in the last 52 weeks of Biogen stock was 220.86. According to the current price, Biogen is 108.22% away from the 52-week low. What was the 52-week high for Biogen stock?

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (78.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (16.7%) ;Manufacturing · Massachusetts, United States · 9,090 Employees. Founded in 1978, Biogen Idec is a biotechnology company specializing in treatments in the areas of immunology and neurology. The company's name-brand drugs include Avonex (for multiple sclerosis), Tysabri (for multiple sclerosis and Crohn's disease), Rituxan (devel Read More.

Biogen Inc. (NASDAQ:AMZN) Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation...Find the latest Eisai Co., Ltd. (4523.T) stock quote, history, news and other vital information to help you with your stock trading and investing.Biogen Inc. (BIIB) NasdaqGS - NasdaqGS Real-time price. Currency in USD. Add to watchlist. 231.95 +0.70 (+0.30%) At close: 01:00PM EST. 232.00 +0.05 (+0.02%) After …The average Biogen stock price prediction forecasts a potential upside of 37.78% from the current BIIB share price of $234.64. What is BIIB's forecast return on equity (ROE) for 2023-2026? ( NASDAQ : BIIB ) forecast ROE is N/A , which is considered weak .

Biogen Inc. (BIIB) closed the most recent trading day at $283.44, moving -1.94% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.49%. Meanwhile, the ...

In addition, Biogen Inc. has a VGM Score of C (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style).

Jul 28, 2023 · Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share ... Biogen Inc stock performance at a glance. Check Biogen Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their trading decisions The top 15 shareholders own 51% of the company Recent sales by insidersStocks / BIIB / Overview Biogen Inc. U.S.: Nasdaq Watchlist market open $ 232.65 BIIB 0.59 0.25% Nov 30, 2023 12:30 p.m. EST Real Time Quote About Biogen Inc. Biogen, Inc. is a...Nov 30, 2023 · As of November 30, 2023, Biogen Inc had a $33.6 billion market capitalization, putting it in the 95th percentile of companies in the Pharmaceuticals industry. Currently, Biogen Inc’s price-earnings ratio is 23.3. Biogen Inc’s trailing 12-month revenue is $10.0 billion with a 14.6% profit margin. Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (78.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (16.7%) ;Wall Street expects a year-over-year decline in earnings on lower revenues when Biogen Inc. (BIIB Quick Quote BIIB - Free Report) reports results for the quarter ended September 2023.While this ...

The stock has a market capitalization of $34.00 billion, a P/E ratio of 23.32, a P/E/G ratio of 2.29 and a beta of 0.08. Biogen ( NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts' …The estimated Net Worth of Michel Vounatsos is at least $36.9 Million dollars as of 18 February 2022. Mr. Vounatsos owns over 6,191 units of Biogen Inc stock worth over $18,755,575 and over the last 7 years he sold BIIB stock worth over $0. In addition, he makes $18,159,900 as Chief Executive Officer and Director at Biogen Inc.Biogen Inc. will be looking to display strength as it nears its next earnings release. In that report, analysts expect Biogen Inc. to post earnings of $3.32 per share. This would mark a year-over ...Jun 10, 2023 · Trading in shares of Biogen remains halted Friday morning as a Food and Drug Administration advisory committee meets to discuss whether the Alzheimer's drug Leqembi from the company and partner ... Biogen Stock Forecast 12-09-2023. Forecast target price for 12-09-2023: $ 231.10. Negative dynamics for Biogen shares will prevail with possible volatility of 3.064%. Pessimistic target level: 225.90. Optimistic target level: 233.04.US09062X1037. Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM …Biogen Inc. Common Stock (BIIB) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

Nov 16, 2023 · Biogen Inc (NASDAQ: BIIB) has a higher price-to-earnings ratio of 22.83x compared to its average ratio, and the 36-month beta value for BIIB is at 0.07. Analysts have varying views on the stock, with 23 analysts rating it as a “buy,” 3 rating it as “overweight,” 8 as “hold,” and 0 as “sell.” The average […]

Description. Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 9,610 full-time employees. The company is focused on discovering, developing and delivering ...The Biogen Inc. stock price gained 0.87% on the last trading day (Thursday, 30th Nov 2023), rising from $232.06 to $234.08.During the last trading day the stock fluctuated 2.56% from a day low at $229.24 to a day high of $235.11.The price has been going up and down for this period, and there has been a 1.94% gain for the last 2 …Cambridge, MA, - - Biogen.com announced today that Priya Sighal, M.D., M.P.H., Head of Development, will participate in the 6th Annual Evercore ISI HealthCONx Conference. The webcast will be live on Tuesday, Nov 28, 2023, at 9:10 a.m. ET. To access the live webcast, please visit the Investors section of Biogen's website at …Get the latest Biogen Inc (IDP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Market Chameleon offers a comparison of Biogen’s fundamentals against those of its peers. Additionally, Infront Analytics provides a market multiple valuation of Biogen Inc. in comparison to its peer group. However, it is essential to acknowledge that short interest and peer comparison are merely two factors to consider when evaluating a …Dec 3, 2023 · Market Average Movement. 6.0%. 10% most volatile stocks in US Market. 15.4%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: BIIB is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week. Volatility Over Time: BIIB's weekly volatility (3%) has been stable over the past year. According to analysts' consensus price target of $323.00, Biogen has a forecasted upside of 37.7% from its current price of $234.64. Amount of Analyst Coverage.Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (78.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (16.7%) ; - other (4.8%): primarily ...

BIIB - Biogen Inc. Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts.com. ... Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment MarketWatch. Monday, August 14, 2023. 07:17 AM ET. Biogen price target cut to $335 from $340 at Mizuho Securities MarketWatch. Monday, August 07, 2023.

In the latest trading session, Biogen Inc. (BIIB) closed at $258.44, marking a -0.19% move from the previous day. This change was narrower than the S&P 500's 0.57% loss on the day.

CAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric ...Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Biogen Inc. (BIIB) stock forecast and price target. Find the latest Biogen Inc. BIIB analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.Jun 10, 2023 · Trading in shares of Biogen remains halted Friday morning as a Food and Drug Administration advisory committee meets to discuss whether the Alzheimer's drug Leqembi from the company and partner ... Invisible Fence Inc. is a leading provider of innovative pet containment and lifestyle solutions. With over 40 years of experience, Invisible Fence Inc. has developed products that are designed to keep pets safe and secure in their own yard...Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (78.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (16.7%) ; - other (4.8%): primarily revenues from partnership agreements.Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and ...Nov 30, 2023 · Complete Biogen Inc. stock information by Barron's. View real-time BIIB stock price and news, along with industry-best analysis. Cambridge, Mass. – JUNE 9, 2023 – Biogen Inc. (Nasdaq: BIIB) announced today that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee is meeting today to review the LEQEMBI™ (lecanemab-irmb) supplemental Biologics License Application (sBLA) for the potential traditional ...Biogen Inc. (BIIB) Acquiree: Reata Pharmaceuticals, Inc. (RETA) Details: Biogen Inc. (NASDAQ:BIIB) - has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases.

The estimated Net Worth of Michel Vounatsos is at least $36.9 Million dollars as of 18 February 2022. Mr. Vounatsos owns over 6,191 units of Biogen Inc stock worth over $18,755,575 and over the last 7 years he sold BIIB stock worth over $0. In addition, he makes $18,159,900 as Chief Executive Officer and Director at Biogen Inc.Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science …Biogen Inc. (BIIB) closed the most recent trading day at $283.44, moving -1.94% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.49%. Meanwhile, the ...Instagram:https://instagram. is it a good time to invest in stocksbutnone month treasuryspacex stock quote Biogen Inc. (BIIB) closed at $262.37 in the latest trading session, marking a +0.01% move from the prior day. This change outpaced the S&P 500's 0.7% loss on the day. Meanwhile, the Dow lost 0.87% ...How much is Biogen Inc stock worth? Invest confidently with precise valuations ... Is Biogen Inc stock a buy? Gain a strategic edge with ratings and sectors ... tesla stock prediction 2024arcteryx used Key Points. Biogen's planned acquisition will add an important product to its portfolio. The company's new Alzheimer's treatment should help it return to growth, too. Even with these developments ... best dave ramsey book Analyst Forecast. According to 25 analysts, the average rating for BIIB stock is "Strong Buy." The 12-month stock price forecast is $329.2, which is an increase of …53.91M. CSCO. 48.04. -9.83%. 78.86M. View today's Biogen Inc stock price and latest BIIB news and analysis. Create real-time notifications to follow any changes in the live stock price.Biogen Inc. (BIIB) closed at $252.86 in the latest trading session, marking a -1.61% move from the prior day.